BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22110199)

  • 1. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
    Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
    Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M
    Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Nakajima T; Mori M
    Lung Cancer; 2009 Oct; 66(1):120-6. PubMed ID: 19171406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Nagamori S; Promchan K; Nakajima T; Yamamoto N; Mori M; Kanai Y
    Anticancer Res; 2010 Dec; 30(12):4819-28. PubMed ID: 21187458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.
    Ichinoe M; Mikami T; Yoshida T; Igawa I; Tsuruta T; Nakada N; Anzai N; Suzuki Y; Endou H; Okayasu I
    Pathol Int; 2011 May; 61(5):281-9. PubMed ID: 21501294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of IGF1R expression in non-small-cell lung cancer.
    Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
    Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
    Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
    Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis.
    Furuya M; Horiguchi J; Nakajima H; Kanai Y; Oyama T
    Cancer Sci; 2012 Feb; 103(2):382-9. PubMed ID: 22077314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
    Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
    Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LAT1 expression in non-small-cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases).
    Takeuchi K; Ogata S; Nakanishi K; Ozeki Y; Hiroi S; Tominaga S; Aida S; Matsuo H; Sakata T; Kawai T
    Lung Cancer; 2010 Apr; 68(1):58-65. PubMed ID: 19559497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
    Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
    Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.